ScreenPoint Medical to Showcase Transpara® Breast AI at ECR 2024

ScreenPoint Medical will showcase its industry leading Transpara Breast AI at the 2024 European Congress of Radiology Meeting (ECR 2024, February 28 – March 3, Vienna).

Transpara provides radiologists with a ‘second pair’ of eyes to help detect cancers earlier and reduce recall rates, delivering proven clinical and workflow benefits in mammography screening in global practice and clinical research.

Transpara is FDA cleared and CE marked for both abnormality detection and density assessment for use with multi-vendor 2D and 3D mammography. Transpara is used by hundreds of leading centres in more than 30 countries and is designed to work alongside radiologists. Research shows that Transpara can detect up to 45% of interval cancers earlier, while helping to improve reading workflow.

We are glad that users and researchers continue to see value from Transpara in improving the mammography screening process. It’s important to note that these studies reflect global consistency in Transpara’s performance. In fact, we now have retrospective, prospective and randomized controlled trials all showing that Transpara provides radiologists with the ability to effectively detect cancer early while keeping recall rates consistent. Women should not have to compromise,” said Mark Koeniguer, CEO of ScreenPoint Medical.

en_GBEnglish (UK)